The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

Insulin-producing cells grown in the lab could offer a functional cure for the disease.

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.

The state’s industry draws inspiration from medicine as well as agriculture.

A list of this year’s newsworthy successes—and failures—in drug development